Finasteride and Tadalafil Interaction: Safety, Mechanisms, and Clinical Guidance

Why These Two Drugs Are Frequently Co-Prescribed

Finasteride and tadalafil target two different components of benign prostatic hyperplasia pathophysiology, making their combined use logical rather than accidental. Finasteride shrinks the prostate by blocking 5-alpha reductase. Tadalafil relaxes smooth muscle in the prostate, bladder neck, and penile vasculature through phosphodiesterase-5 inhibition.

The Medical Therapy of Prostatic Symptoms (MTOPS) trial (N=3,047) established that combination medical therapy for BPH reduces disease progression more effectively than monotherapy. That study paired finasteride with doxazosin, but the principle of dual-mechanism therapy carries forward into current practice patterns that substitute tadalafil for alpha-blockers in select patients [1]. The FDA approved tadalafil 5 mg daily for BPH/LUTS in 2011 based on four randomized controlled trials totaling over 1,500 men, establishing it as a standalone option for lower urinary tract symptoms [2].

Men taking finasteride 1 mg for androgenetic alopecia who also have erectile dysfunction represent the other common clinical scenario. These patients may receive tadalafil for on-demand or daily ED management. The interaction profile matters to both groups, but for different reasons. BPH patients are older, take higher finasteride doses, and carry more cardiovascular risk. Hair-loss patients are younger but may be more sensitive to sexual side-effect stacking.

Pharmacokinetic Profile: No Meaningful Metabolic Conflict

Both drugs undergo hepatic CYP3A4 metabolism, but finasteride does not inhibit or induce CYP3A4 at clinically relevant concentrations. This is the single most important pharmacokinetic fact about this pairing.

Finasteride is a CYP3A4 substrate with minor contributions from CYP1A2, CYP2C9, and CYP2C19. Its hepatic extraction ratio is low, and it does not function as a CYP inhibitor or inducer at doses of 1 mg or 5 mg daily [3]. Tadalafil is also a CYP3A4 substrate, with no significant CYP3A4 inhibitory activity [4]. Because neither drug meaningfully alters CYP3A4 enzyme activity, co-administration does not change the area under the curve (AUC), peak plasma concentration (Cmax), or half-life of the other compound.

Protein binding also poses no issue. Finasteride is approximately 90% bound to plasma proteins. Tadalafil is 94% protein-bound, primarily to albumin. Displacement interactions become clinically significant only when a drug is greater than 99% protein-bound and has a narrow therapeutic index. Neither criterion applies here.

No formal drug-drug interaction study between finasteride and tadalafil has been published on PubMed, which itself reflects the low pharmacokinetic concern. The FDA labels for both drugs do not list the other as an interacting medication [3][4]. The Lexicomp and Micromedex DDI databases classify this pairing as having no documented pharmacokinetic interaction.

Pharmacodynamic Interactions: Where Monitoring Matters

The pharmacodynamic overlap between finasteride and tadalafil deserves more clinical attention than the pharmacokinetic profile. Two areas require consideration: blood pressure effects and sexual function.

Blood pressure. Tadalafil produces mild systemic vasodilation. In healthy volunteers, tadalafil 20 mg reduced mean supine systolic blood pressure by 1.6 mmHg, according to the FDA label [4]. Finasteride does not directly lower blood pressure, but dizziness is listed as an adverse event occurring in 1.2% of patients in the Proscar Long-Term Efficacy and Safety Study (PLESS, N=3,040) [3]. Patients taking both drugs who also use antihypertensives, alpha-blockers, or nitrates need explicit counseling. The absolute contraindication for tadalafil remains concurrent nitrate use due to the risk of severe, potentially fatal hypotension [4].

Sexual function. Finasteride 1 mg causes decreased libido in 1.8% of men and erectile dysfunction in 1.3%, based on the key hair-loss trials [3]. At the 5 mg BPH dose, sexual adverse events were reported by 3.7% in the PLESS trial [5]. Tadalafil, conversely, is prescribed to treat erectile dysfunction. The apparent paradox of combining a drug that may impair erections with one that treats them is actually part of the clinical rationale. Some clinicians prescribe tadalafil specifically to offset finasteride-related sexual side effects, though randomized evidence supporting this strategy remains limited.

A 2019 retrospective cohort study of 470 men receiving finasteride for hair loss found that those co-prescribed a PDE5 inhibitor reported significantly fewer sexual complaints at 12-month follow-up compared to finasteride-only users, though the study lacked randomization and blinding [6]. This signals plausibility but not proof.

Real-World Combination Use in BPH: The CombAT and MTOPS Context

The strongest evidence for combining a 5-alpha reductase inhibitor with a second urological agent comes from the CombAT trial (N=4,844), which paired dutasteride (finasteride's pharmacological cousin) with tamsulosin [7]. At 4 years, combination therapy reduced BPH progression risk by 65.8% relative to tamsulosin alone. The MTOPS trial showed that finasteride plus doxazosin reduced clinical progression by 66% versus placebo over a mean follow-up of 4.5 years [1].

Neither trial used tadalafil as the combination partner. The evidence base for finasteride plus tadalafil specifically is thinner. A 2015 systematic review in the European Urology journal evaluated PDE5 inhibitors combined with alpha-blockers or 5-alpha reductase inhibitors for LUTS/BPH and concluded that PDE5 inhibitors improve International Prostate Symptom Score (IPSS) and erectile function when added to existing BPH therapy, though most combination data involved alpha-blockers rather than 5-ARIs [8].

Clinicians choosing this combination typically do so when a patient has both BPH-LUTS and ED, aiming to address both conditions while avoiding the orthostatic hypotension risk associated with alpha-blocker plus tadalafil combinations. This pragmatic approach has pharmacological logic. It lacks dedicated RCT support.

Dose Considerations and Adjustment

No dose adjustment is required for either drug when prescribed together. The standard dosing applies.

For BPH: finasteride 5 mg daily plus tadalafil 5 mg daily. This mirrors the FDA-approved doses for each drug's BPH indication. Neither drug's label recommends dose modification when the other is co-administered.

For hair loss with ED management: finasteride 1 mg daily plus tadalafil as needed (10 mg or 20 mg before sexual activity) or tadalafil 2.5 to 5 mg daily. The choice between on-demand and daily tadalafil depends on the frequency of sexual activity and patient preference, not on the finasteride co-prescription [4].

Renal impairment changes the calculation for tadalafil but not finasteride. For patients with creatinine clearance 30 to 50 mL/min, tadalafil daily dosing should not exceed 2.5 mg, and on-demand dosing should start at 5 mg with a maximum of 10 mg every 48 hours [4]. Finasteride requires no renal adjustment. Hepatic impairment has not been studied for finasteride in patients with liver disease; tadalafil exposure increases in mild to moderate hepatic impairment (Child-Pugh A or B), and the drug is not recommended in severe hepatic impairment [4].

Patients taking strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) need tadalafil dose reduction regardless of finasteride status. The maximum recommended tadalafil dose with a strong CYP3A4 inhibitor is 10 mg every 72 hours for on-demand use [4].

Monitoring Recommendations

Routine laboratory monitoring is not required specifically because of this drug combination. Standard monitoring for each drug individually applies.

For finasteride: PSA levels. Finasteride reduces serum PSA by approximately 50% after 6 months of use. Any PSA value obtained in a patient on finasteride should be doubled for comparison to normal ranges. The American Urological Association recommends baseline PSA before starting 5-alpha reductase inhibitors and periodic reassessment [9]. A confirmed PSA rise during finasteride therapy, even if the absolute number appears low, warrants urological evaluation.

For tadalafil: blood pressure at baseline, particularly in patients on antihypertensives. Visual changes (especially blue-tinged vision, which is more common with sildenafil but possible with all PDE5 inhibitors) and priapism risk should be discussed. Hearing changes, though rare (reported incidence below 0.1%), require immediate medical attention [4].

For both drugs together: a focused sexual-function history at 3 and 6 months. Ask specifically about libido, erectile function, ejaculatory volume, and orgasm quality. If sexual complaints emerge, determine whether the timeline correlates with finasteride initiation or with another factor. The nocebo effect is well-documented for finasteride sexual side effects. A 2021 study in JAMA Dermatology (N=234) found that men informed about finasteride's sexual side effects were significantly more likely to report them than uninformed controls, with a relative risk of 3.29 [10].

Patient Counseling Points

Three conversations matter when prescribing this combination.

First: nitrate safety. Any man taking tadalafil must understand that nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, and recreational amyl nitrite ("poppers") are absolutely contraindicated. This applies even if tadalafil was taken 48 hours prior, given its 17.5-hour half-life [4]. This counseling point is about tadalafil, not the combination, but it becomes more relevant when patients are managing multiple prescriptions.

Second: timeline expectations. Finasteride requires 3 to 6 months for hair-loss efficacy and 6 to 12 months for maximal BPH symptom improvement. Tadalafil produces effects within 30 minutes for on-demand use and within 5 days of daily dosing for steady-state LUTS benefit [4]. Patients expecting both drugs to work on the same timeline will be disappointed.

Third: fertility. Finasteride reduces semen volume by approximately 25% and can decrease sperm count in some men [3]. Tadalafil does not impair spermatogenesis at approved doses. Men planning conception should discuss finasteride discontinuation with their prescriber. The Endocrine Society recommends stopping finasteride at least 3 months before planned conception attempts due to its teratogenic potential for male fetuses exposed through seminal fluid contact with pregnant partners [11].

When to Avoid This Combination

There are no absolute contraindications to co-prescribing finasteride and tadalafil based on their interaction profile. Situations where the combination warrants extra caution or alternative approaches include the following.

Patients with orthostatic hypotension already on alpha-blockers. Adding tadalafil to finasteride plus tamsulosin creates a triple-therapy scenario where cumulative vasodilatory effects may produce symptomatic drops in standing blood pressure. If an alpha-blocker is already prescribed, the tadalafil dose should not exceed 5 mg daily, and it should be initiated at 2.5 mg with careful blood-pressure monitoring [4].

Patients with unstable cardiovascular disease. The ACC/AHA guidelines recommend against PDE5 inhibitor use in patients who have had a myocardial infarction within 90 days, unstable angina, NYHA Class III or IV heart failure, uncontrolled arrhythmias, or blood pressure below 90/50 mmHg [12]. Finasteride does not add cardiovascular risk, but it also does not reduce it.

Young men with psychogenic sexual dysfunction attributed to finasteride. In this population, the concern is not pharmacological interaction but diagnostic clarity. Prescribing tadalafil to counteract reported finasteride side effects may mask whether the sexual complaint is pharmacological, psychological, or nocebo-driven. A structured washout period for finasteride, with validated sexual function questionnaires (IIEF-5) before and after, provides better diagnostic information than empiric PDE5 inhibitor addition.

The Bottom Line on CYP3A4 Substrate Overlap

Sharing a metabolic enzyme does not equal a drug interaction. Two CYP3A4 substrates only compete meaningfully when at least one has high hepatic extraction, narrow therapeutic index, or significant enzyme inhibition properties. Finasteride has none of these characteristics at clinical doses, and tadalafil's therapeutic window is wide enough that modest pharmacokinetic variation does not produce toxicity. The drugs can be taken at the same time of day without timing separation.

Prescribers should document the combination in the patient's medication list, counsel on nitrate avoidance, and schedule a sexual-function check at 3 to 6 months. Men taking finasteride 1 mg for hair loss can safely add tadalafil 5 mg daily or on-demand dosing without dose modification, provided they have no cardiovascular contraindications to PDE5 inhibitor therapy.